UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buys
1/7
Pharma Bets
Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both 'Buy' and 'Sell' ratings on a range of pharmaceutical stocks.
Here is a list of 6 pharma stocks on which UBS initiated coverage:
Here is a list of 6 pharma stocks on which UBS initiated coverage:
2/7
Sun Pharma | CMP: Rs 1,949
Global Brokerage firm UBS initiated coverage on Sun Pharma with a 'Buy' rating. The brokerage firm set a target price of Rs 2,450 on the stock, which shows an upside potential of 26% from the current market prices.
3/7
Cipla | CMP: Rs 1,671
UBS initiated coverage on Cipla with a Buy rating. The brokerage firm set a target price of Rs 2,060 on the stock, which implies an upside potential of 23% from the current market prices.
Amazon Top Deals
POWERED BY
Crompton Ozone 75 Litres Desert Air Cooler for home | Large & Easy Clean Ice Chamber | 4-Way Air Deflection | High Density Honeycomb Pads | Everlast Pump | Auto Fill| 3 Year Brand Warranty
₹9,798Buy Now43%
OFF
atomberg Studio Smart+ 1200mm BLDC Ceiling Fan with IoT & Remote | BEE 5 star Rated Energy Efficient Ceiling Fan | High Air Delivery with LED Indicators | 3 Year Warranty (Earth Brown)
₹5,882Buy Now36%
OFF
LG 32 L Convection Microwave Oven (MC3286BRUM, Black, 360° Motorised Rotisserie for Bar-be-queing, 301 Auto Cook Menu, Stainless steel cavity, Indian Cuisine, Tandoor Se, Steam Clean & Diet Fry)
₹19,340Buy Now19%
OFF
4/7
Lupin | CMP: Rs 2,221
UBS initiated coverage on Lupin with a 'Sell' rating. However, the brokerage firm set a target price of Rs 2,250 on the stock, which shows an upside of 2% from the current market prices.
5/7
Zydus Life | CMP: Rs 1,074
UBS initiated coverage on Zydus Life with a 'Sell' rating. The brokerage firm set a target price of Rs 850 on the stock, which indicates a downside potential of 21% from the current market prices.
6/7
Dr Reddy's Labs | CMP: Rs 6,755
UBS initiated coverage on Dr Redyy's Laboratories with a 'Sell' rating. The brokerage firm set a target price of Rs 5,700 on the stock, which implies a downside of 16% from the current market prices.
7/7
Aurobindo Pharma | CMP: Rs 1,510
UBS initiated coverage on Aurobindo Pharma with a 'Sell' rating. The brokerage firm set a target price of Rs 1,333 on the stock, which shows a downside of 12% from the current market prices.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)